Observational studyMedicine2025
Association of systemic immune-inflammation index and aggregate index of systemic inflammation with clinical status in stable and exacerbated COPD: A single-center retrospective study.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Clinical Cut-Off Value for the Systemic Immune-Inflammation Index to Predict Frequent Exacerbations in Stable COPD.Medicina (Kaunas, Lithuania) · 2026Observational
- Risk Factors and Prediction of Chronic Obstructive Pulmonary Disease After Pulmonary Tuberculosis: A Prospective Cohort Study.International journal of chronic obstructive pulmonary disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is a condition characterized by persistent airflow limitation and inflammation. Exacerbations may occur even during the stable phase of COPD, which significantly affects patients' quality of life. This study investigates the association of the Systemic Immune-Inflammation Index (SII) and the Aggregate Index of Systemic Inflammation (AISI) with clinical status in COPD patients during stable and exacerbation phases. This retrospective study included 245 patients diagnosed with COPD between 2020 and 2025. The patients were divided into 2 groups: stable COPD (n = 120) and COPD exacerbation (n = 125). The demographic characteristics, pulmonary function tests, and biomarkers (SII, AISI) of the patients were retrospectively analyzed. Statistical significance level was accepted as P < .05. In the exacerbation group, the SII and AISI values were significantly higher compared to the stable group (SII: 2782.32 ± 439.56, AISI: 1242.6 ± 239.91, P < .001). A strong positive correlation was found between SII and AISI with hospital admission in the exacerbation group (SII: R = 0.824, AISI: R = 0.956, P < .001). In the ROC analysis performed to predict the exacerbation group, cutoff values of 688.8 for SII and 397.56 for AISI yielded AUC values of 0.962 and 0.938, respectively. Multivariate logistic regression analysis revealed that both SII (OR: 1.001, 95% CI: 1.000-1.002, P = .031) and AISI (OR: 1.003, 95% CI: 1.001-1.005, P = .002) serve as independent predictors of COPD exacerbation. SII and AISI are useful biomarkers associated with the clinical status of COPD patients in both stable and exacerbation phases. High SII and AISI values can accurately predict exacerbation and hospital admission risk, thus aiding in the more effective management of treatment processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.